On this page of StockholderLetter.com we present the 4/24/2023 shareholder letter from Keros Therapeutics, Inc. — ticker symbol KROS. Reading current and past KROS letters to shareholders can bring important insights into the investment thesis.
2022 ANNUAL REPORT Corporate Headquarters 1050 Waltham Street, Suite 302 Lexington, MA 02421 www.kerostx.com NASDAQ: KROS
 • shareholder letter icon 4/24/2023 Letter Continued (Full PDF)
 • stockholder letter icon 4/17/2024 KROS Stockholder Letter
 • stockholder letter icon More "Biotechnology" Category Stockholder Letters
 • Benford's Law Stocks icon KROS Benford's Law Stock Score = 36


KROS 4/24/2023 Shareholder/Stockholder Letter Transcript:

2022
ANNUAL REPORT
Corporate Headquarters
1050 Waltham Street, Suite 302
Lexington, MA 02421
www.kerostx.com
NASDAQ: KROS




shareholder letter icon 4/24/2023 Letter Continued (Full PDF)
 

KROS Stockholder/Shareholder Letter (Keros Therapeutics, Inc.) 4/24/2023 | www.StockholderLetter.com
Copyright © 2023 - 2025, All Rights Reserved

Nothing in StockholderLetter.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy.